Back to search

France· FR:69325035

FOSTIMONKIT 300 UI, poudre et solvant pour solution injectable

A urofollitropin product containing urofollitropine, registered in France by IBSA PHARMA SAS, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC G03GA04

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedFOSTIMONKIT 300 UI, poudre et solvant…ATCG03GA04REGISTER NO.FR:69325035PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Urofollitropin is registered in 11 of 19 countries.

Countries holding a registration under ATC G03GA04 (urofollitropin), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 7 of them publish a price we can compare per daily dose

Urofollitropin · ATC G03GA04

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
UROFOLLITROPINE
Manufacturer
IBSA PHARMA SAS
Country
France (FR)
ATC code
G03GA04
ATC class
Urofollitropin
Defined daily dose
75 E, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400927436277
    5 flacon(s) de poudre en verre - 5 seringue(s) préremplie(s) de solvant en verre de 1 ml avec aiguille(s)
    EUR 275.53

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for urofollitropin.

Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Urofollitropin · interactions on record

1 record

  • 1 moderate

Most severe, free to view

  • GanirelixH01CC01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Urofollitropin in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All urofollitropin products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

  • Austria · Fostimon, Fostimon Pfs
  • Belgium · Fostimon, Fostimon Kit
  • Bulgaria · Фостимон
  • Cyprus · Fostimon, Fostimon Pfs
  • Czechia · Fostimon
  • Denmark · Fostimon, Fostimon Set
  • Spain · Fostipur, Fostipur Kit
  • Finland · Fostimon, Fostimon Set
  • United Kingdom (Northern Ireland) · Fostimon, Fostimon Pfs
  • Greece · Altermon
  • Hungary · Fostimon Hp
  • Ireland · Fostimon, Fostimon Pfs
  • Italy · Fostimon
  • Luxembourg · Fostimon, Fostimon Kit
  • Netherlands · Fostimon, Fostimon Set
  • Norway · Fostimon, Fostimon Set
  • Poland · Fostimon
  • Sweden · Fostimon, Fostimon Set
  • Slovakia · Fostimon Hp

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9ba2d846-afbe-4c74-8943-e7de97b3a6ab
GET /v1/drugs/9ba2d846-afbe-4c74-8943-e7de97b3a6ab?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69325035",
  "date_amm": "2013-07-09",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "UROFOLLITROPINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": "Warning disponibilité",
  "forme_pharmaceutique": "poudre et  solvant pour solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Non commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about urofollitropin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.